"New treatments (pharmacological and device based) are currently in development to expand our OAB armamentarium," write Nathan Chertack, MD, and Gary Lemack, MD.
Gary Lemack, MD
Advertisement
Articles by Gary Lemack, MD
Advertisement
Latest Updated Articles
New developments may change treatment of OABApril 21st 2020
Advertisement
Advertisement
Trending on Urology Times
1
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer
2
Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC
3
Elizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab
4
Optimizing care for men with overactive bladder, with Keith Xavier, MD
5